Kissei Pharmaceutical Co., Ltd.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1946-08-09
- Employees
- 1.7K
- Market Cap
- -
- Website
- http://www.kissei.co.jp
Special Drug Use-results Survey for Long-term Use (Fostamatinib)
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 149
- Registration Number
- NCT06757257
- Locations
- 🇯🇵
Research site, Tokyo And Japanese Other Cities, Japan
Special Drug Use-results Survey for Long-term Use（Avacopan）
Recruiting
- Conditions
- Microscopic Polyangiitis (MPA)Granulomatosis With Polyangiitis (GPA)
- Interventions
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT06758271
- Locations
- 🇯🇵
Research site, Multiple Locations, Japan
A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06722729
- Locations
- 🇯🇵
Research Site, Multiple Locations, Japan
An Early Phase 2 Clinical Study of KSP-0243
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05831670
- Locations
- 🇯🇵
Research Site, Multiple Locations, Japan
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain
Phase 3
Completed
- Conditions
- Uterine Fibroids (MeSH Heading: Leiomyoma)
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 89
- Registration Number
- NCT05445167
- Locations
- 🇯🇵
Clinical Research Site, Multiple Locations, Japan
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
Phase 3
Completed
- Conditions
- Uterine Fibroids (MeSH Heading: Leiomyoma)
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 287
- Registration Number
- NCT05440383
- Locations
- 🇯🇵
Clinical Resarch Site, Multiple Locations, Japan
A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT04867551
- Locations
- 🇯🇵
Research Site, Multiple Locations, Japan
A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 178
- Registration Number
- NCT04711603
- Locations
- 🇯🇵
Research Site, Multiple Locations, Japan
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain
Phase 3
Terminated
- Conditions
- Endometriosis
- Interventions
- Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg)Drug: Placebo capsule to match Add-back capsule
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04372121
- Locations
- 🇺🇸
Applied Res Center of Ar / Id # 735, Little Rock, Arkansas, United States
🇺🇸Dr. David I. Lubetkin, LLC / ID # 703, Boca Raton, Florida, United States
🇺🇸HCWC dba DiscoveryClinical Trials / ID # 771, Dallas, Texas, United States
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)
Phase 3
Completed
- Conditions
- Endometriosis
- Interventions
- Drug: Placebo capsule to match Add-back capsuleDrug: Add-back capsule (E2 1 mg / NETA 0.5 mg)
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 356
- Registration Number
- NCT04335591
- Locations
- 🇵🇱
Specjalistyczny Gabinet Lekarski Krzysztof Dynowski / ID # 401, Warsaw, Poland
🇺🇸Universal Axon - Homestead, LLC/ ID # 620, Homestead, Florida, United States
🇺🇸Stedman Clinical Trials/ ID # 612, Tampa, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath